Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business.